Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer

NCT00002947 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

35

Enrollment

OTHER

Sponsor class

Conditions

Brain and Central Nervous System Tumors
Childhood Langerhans Cell Histiocytosis
Gastrointestinal Carcinoid Tumor
Head and Neck Cancer
Intraocular Melanoma
Islet Cell Tumor
Kidney Cancer
Lung Cancer
Melanoma (Skin)
Neoplastic Syndrome
Neuroendocrine Carcinoma of the Skin
Pheochromocytoma

Interventions

RADIATION: indium In 111 pentetreotide

Sponsor

Yale University

Collaborators

[object Object]